NCT06797349

Brief Summary

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jan 2025

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 21, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

January 23, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 28, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 4, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 4, 2025

Completed
Last Updated

May 23, 2025

Status Verified

May 1, 2025

Enrollment Period

1 month

First QC Date

January 21, 2025

Last Update Submit

May 22, 2025

Conditions

Keywords

Glycemic responseGlycemic IndexNutritional productsHealthy Individuals

Outcome Measures

Primary Outcomes (1)

  • The glycemic index of nutritional products

    from enrollment to the end of treatment at about 9 weeks

Secondary Outcomes (2)

  • 1. The postprandial glucose levels at each time point after each test product compared with the mean of the 3 references

    from enrollment to the end of treatment at about 9 weeks

  • 2. The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 references

    from enrollment to the end of treatment at about 9 weeks

Study Arms (10)

Arm 1

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: First Reference product

Arm 2

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Second reference product

Arm 3

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Third reference product

Arm 4

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: First Concept product

Arm 5

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Second Concept product

Arm 6

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Third Concept product

Arm 7

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Fourth Concept product

Arm 8

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Fifth Concept product

Arm 9

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Sixth Concept product

Arm 10

OTHER

All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.

Dietary Supplement: Seventh Concept product

Interventions

First Reference productDIETARY_SUPPLEMENT

dextrose (containing 25 grams of carbohydrates)

Arm 1
Second reference productDIETARY_SUPPLEMENT

dextrose (containing 25 grams of carbohydrates)

Arm 2
Third reference productDIETARY_SUPPLEMENT

dextrose (containing 25 grams of carbohydrates)

Arm 3
First Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)

Arm 4
Second Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)

Arm 5
Third Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)

Arm 6
Fourth Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)

Arm 7
Fifth Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates

Arm 8
Sixth Concept productDIETARY_SUPPLEMENT

Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates

Arm 9
Seventh Concept productDIETARY_SUPPLEMENT

High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates

Arm 10

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 and ≤ 65 years
  • Body mass index (BMI) between 18.5 and 27 kg/m²

You may not qualify if:

  • Baseline fasting Glucose ≥6.1 at screening visit
  • Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results.
  • Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
  • Major trauma or surgical event within 3 months of screening.
  • Known intolerance, sensitivity or allergy to test products.
  • Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
  • History of cancer in the prior two years, except for non-melanoma skin cancer.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INQUIS Clinical Research, Ltd , 20 Victoria Street, 3rd Floor

Toronto, Ontario, M5C 2N8, Canada

Location

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: 10 products will be tested (7 test products and 3 controls)
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 21, 2025

First Posted

January 28, 2025

Study Start

January 23, 2025

Primary Completion

March 4, 2025

Study Completion

March 4, 2025

Last Updated

May 23, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations